| 000 | 01530 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250513031350.0 | ||
| 264 | 0 | _c19950210 | |
| 008 | 199502s 0 0 eng d | ||
| 022 | _a0733-1959 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBostwick, D G | |
| 245 | 0 | 0 |
_aThe most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials. _h[electronic resource] |
| 260 |
_bJournal of cellular biochemistry. Supplement _c1994 |
||
| 300 |
_a283-9 p. _bdigital |
||
| 500 | _aPublication Type: Consensus Development Conference; Journal Article; Review | ||
| 650 | 0 | 4 |
_aAnticarcinogenic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xanalysis |
| 650 | 0 | 4 | _aClinical Trials, Phase II as Topic |
| 650 | 0 | 4 |
_aDNA, Neoplasm _xanalysis |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMass Screening |
| 650 | 0 | 4 | _aNeovascularization, Pathologic |
| 650 | 0 | 4 | _aPloidies |
| 650 | 0 | 4 | _aPredictive Value of Tests |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aProstate-Specific Antigen _xanalysis |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xblood |
| 650 | 0 | 4 |
_aReceptor, ErbB-2 _xanalysis |
| 700 | 1 | _aBurke, H B | |
| 700 | 1 | _aWheeler, T M | |
| 700 | 1 | _aChung, L W | |
| 700 | 1 | _aBookstein, R | |
| 700 | 1 | _aPretlow, T G | |
| 700 | 1 | _aNagle, R B | |
| 700 | 1 | _aMontironi, R | |
| 700 | 1 | _aLieber, M M | |
| 700 | 1 | _aVeltri, R W | |
| 773 | 0 |
_tJournal of cellular biochemistry. Supplement _gvol. 19 _gp. 283-9 |
|
| 999 |
_c7529317 _d7529317 |
||